WO2007011760A3 - Inhibiteurs de la kinesine mitotique - Google Patents
Inhibiteurs de la kinesine mitotique Download PDFInfo
- Publication number
- WO2007011760A3 WO2007011760A3 PCT/US2006/027450 US2006027450W WO2007011760A3 WO 2007011760 A3 WO2007011760 A3 WO 2007011760A3 US 2006027450 W US2006027450 W US 2006027450W WO 2007011760 A3 WO2007011760 A3 WO 2007011760A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- inhibitors
- mitotic kinesin
- kinesin
- mitotic
- ksp
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention porte sur des composés et des procédés d'inhibition de la kinésine mitotique (KSP) pour traiter ou prévenir les maladies à prolifération cellulaire.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69952305P | 2005-07-15 | 2005-07-15 | |
US60/699,523 | 2005-07-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007011760A2 WO2007011760A2 (fr) | 2007-01-25 |
WO2007011760A3 true WO2007011760A3 (fr) | 2007-09-07 |
Family
ID=37433779
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/027450 WO2007011760A2 (fr) | 2005-07-15 | 2006-07-13 | Inhibiteurs de la kinesine mitotique |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2007011760A2 (fr) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7629346B2 (en) | 2006-06-19 | 2009-12-08 | Hoffmann-La Roche Inc. | Pyrazinecarboxamide derivatives as CB1 antagonists |
BRPI0717845A2 (pt) | 2006-10-04 | 2015-06-16 | Hoffmann La Roche | Uso de compostos, composições farmacêuticas e métodos para o tratamento e/ou profilaxia de enfermidades que podem ser tratadas com agentes de elevação de colesterol-hdl e compostos |
CA2741644C (fr) | 2008-10-30 | 2013-05-07 | Merck Sharp & Dohme Corp. | Antagonistes d'isonicotinamide des recepteurs de l'orexine |
US8410107B2 (en) | 2010-10-15 | 2013-04-02 | Hoffmann-La Roche Inc. | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides |
US8669254B2 (en) | 2010-12-15 | 2014-03-11 | Hoffman-La Roche Inc. | Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents |
US9321727B2 (en) * | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
CN103781765A (zh) * | 2011-09-12 | 2014-05-07 | 霍夫曼-拉罗奇有限公司 | 作为hdl-胆固醇升高剂的3-吡啶甲酰肼类 |
ES2649156T3 (es) | 2013-01-14 | 2018-01-10 | Incyte Holdings Corporation | Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim |
BR112015016793B1 (pt) | 2013-01-15 | 2021-12-28 | Incyte Holdings Corporation | Compostos de tiazolacarboxamidas e piridinacarboxamida, composição compreendendo os mesmos, método de inibição da enzima pim1, pim2, ou pim3, e usos dos referidos compostos |
US9556197B2 (en) | 2013-08-23 | 2017-01-31 | Incyte Corporation | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors |
EP3140298A1 (fr) | 2014-05-07 | 2017-03-15 | Pfizer Inc. | Inhibiteurs de kinases apparentées à la tropomyosine |
US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
AU2015315177A1 (en) * | 2014-09-10 | 2017-03-16 | Epizyme, Inc. | Substituted pyrrolidine carboxamide compounds |
US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
BR112018004065B1 (pt) | 2015-08-31 | 2023-12-12 | Dong-A Socio Holdings Co., Ltd | Compostos heterocíclicos, composições farmacêuticas compreendendo os ditos compostos e usos terapêuticos dos mesmos |
AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
WO2017059251A1 (fr) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Composés hétérocycliques utiles en tant qu'inhibiteurs de la kinase pim |
WO2018014829A1 (fr) | 2016-07-20 | 2018-01-25 | Novartis Ag | Dérivés de l'aminopyridine et leur utilisation en tant qu'inhibiteurs sélectifs d'alk-2 |
EP3523292B1 (fr) * | 2016-10-10 | 2021-12-15 | Dong-A Socio Holdings Co., Ltd. | Composés hétéroaryle et leur utilisation en tant qu'inhibiteurs de mer |
TW201924683A (zh) | 2017-12-08 | 2019-07-01 | 美商英塞特公司 | 用於治療骨髓增生性贅瘤的低劑量組合療法 |
CN108524947B (zh) * | 2018-05-04 | 2019-08-09 | 北京林业大学 | 一种具有pH响应的灵芝多糖-苯硼酸-甲氨蝶呤结合物载药纳米粒子及其制备方法 |
JP2023502742A (ja) | 2019-11-22 | 2023-01-25 | インサイト コーポレーション | Alk2阻害剤及びjak2阻害剤を含む併用療法 |
IL298767A (en) | 2020-06-16 | 2023-02-01 | Incyte Corp | ALK2 inhibitors for the treatment of anemia |
WO2023008973A1 (fr) * | 2021-07-29 | 2023-02-02 | 프라비바이오 주식회사 | Nouveau dérivé de benzène et son utilisation associée à l'immunosuppression |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001027085A1 (fr) * | 1999-10-13 | 2001-04-19 | Merck Frosst Canada & Co. | Utilisation de comme inhibiteurs de la caspase-3 nicotinyl aspartyl ketones as inhibitors of caspase-3 |
US20030055088A1 (en) * | 2001-09-07 | 2003-03-20 | Euro-Celtique S.A. | Aryl substituted pyridines and the use thereof |
EP1308441A1 (fr) * | 2000-08-11 | 2003-05-07 | Eisai Co., Ltd. | Composes 2-aminopyridine et leur utilisation comme medicaments |
WO2003082191A2 (fr) * | 2002-03-28 | 2003-10-09 | Merck & Co., Inc. | 2,3-diphenyl-pyridines substituees |
WO2004054977A1 (fr) * | 2002-12-13 | 2004-07-01 | Cytopia Pty Ltd | Inhibiteurs de kinase a base de nicotinamide |
WO2006086600A1 (fr) * | 2005-02-11 | 2006-08-17 | Cephalon, Inc. | Inhibiteurs du proteasome et leurs methodes d'utilisation |
WO2006106054A1 (fr) * | 2005-04-06 | 2006-10-12 | F. Hoffmann-La Roche Ag | Derives de pyridine-3-carboxamide utilises comme agonistes inverses des cb1 |
-
2006
- 2006-07-13 WO PCT/US2006/027450 patent/WO2007011760A2/fr active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001027085A1 (fr) * | 1999-10-13 | 2001-04-19 | Merck Frosst Canada & Co. | Utilisation de comme inhibiteurs de la caspase-3 nicotinyl aspartyl ketones as inhibitors of caspase-3 |
EP1308441A1 (fr) * | 2000-08-11 | 2003-05-07 | Eisai Co., Ltd. | Composes 2-aminopyridine et leur utilisation comme medicaments |
US20030055088A1 (en) * | 2001-09-07 | 2003-03-20 | Euro-Celtique S.A. | Aryl substituted pyridines and the use thereof |
WO2003082191A2 (fr) * | 2002-03-28 | 2003-10-09 | Merck & Co., Inc. | 2,3-diphenyl-pyridines substituees |
WO2004054977A1 (fr) * | 2002-12-13 | 2004-07-01 | Cytopia Pty Ltd | Inhibiteurs de kinase a base de nicotinamide |
WO2006086600A1 (fr) * | 2005-02-11 | 2006-08-17 | Cephalon, Inc. | Inhibiteurs du proteasome et leurs methodes d'utilisation |
WO2006106054A1 (fr) * | 2005-04-06 | 2006-10-12 | F. Hoffmann-La Roche Ag | Derives de pyridine-3-carboxamide utilises comme agonistes inverses des cb1 |
Non-Patent Citations (2)
Title |
---|
BECKER, JOSEPH W. ET AL BECKER, JOSEPH W. ET AL: "Reducing the Peptidyl Features of Caspase-3 Inhibitors: A Structural Analysis Reducing the Peptidyl Features of Caspase-3 Inhibitors: A Structural Analysis", JOURNAL OF MEDICINAL CHEMISTRY , 47(10), 2466-2474 CODEN: JMCMAR; ISSN: 0022-2623 JOURNAL OF MEDICINAL CHEMISTRY , 47(10), 2466-2474 CODEN: JMCMAR; ISSN: 0022-2623, 2004, XP002425660 * |
BIN SHAO ET AL: "Phenoxyphenyl Pyridines as novel State-Dependent, High-Potency Sodium Channel Inhibitors", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 47, no. 17, 2004, pages 4277 - 4285, XP002413029, ISSN: 0022-2623 * |
Also Published As
Publication number | Publication date |
---|---|
WO2007011760A2 (fr) | 2007-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007011760A3 (fr) | Inhibiteurs de la kinesine mitotique | |
WO2007011759A3 (fr) | Inhibiteurs de la kinesine mitotique | |
WO2008011560A3 (fr) | Inhibiteurs de la rho kinase à base de benzothiophène | |
WO2007085895A3 (fr) | Inhibiteurs fap | |
WO2008131000A3 (fr) | Inhibiteurs mcl-1 indole 7-substitués | |
WO2006113919A3 (fr) | Preparation et utilisation de derives de l'acide aryle alkyle dans le traitement de l'obesite | |
WO2008083252A3 (fr) | Procédés d'utilisation pour des analogues de cyclopamine | |
WO2008079988A3 (fr) | Quinazolines destinés à l'inhibition de pdk1 | |
WO2008033562A3 (fr) | Composés inhibiteurs de kinases | |
TW200700422A (en) | Compounds for inhibiting ksp kinesin activity | |
EP1804794A4 (fr) | Composes de spiropiperidine utilises comme inhibiteurs de beta-secretase en vue du traitement de la maladie d'alzheimer | |
WO2012040641A3 (fr) | Composés de traitement de maladies neurodégénératives | |
WO2007025090A3 (fr) | Inhibiteurs de kinase mapk/erk | |
WO2008112199A8 (fr) | Procédé d'inhibition de la topoisomérase ii | |
WO2006023651A3 (fr) | Traitement prolonge de la sclerose en plaques | |
WO2006050161A3 (fr) | Furopyrimidines et thienopyrimidines therapeutiques | |
WO2008060767A3 (fr) | Dérivés de pyrimidine benzocondensés macrocycliques | |
WO2006078287A3 (fr) | Inhibiteurs de pde4b | |
WO2008051416A3 (fr) | Procede permettant de traiter des infections | |
TW200626068A (en) | Active compounds for seed treatment | |
WO2009051670A3 (fr) | Compositions et procédés destinés au traitement de maladies ophtalmiques | |
WO2006044775A3 (fr) | Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite | |
WO2008067219A3 (fr) | Modulateurs quinazolinones de tgr5 | |
WO2007123892A3 (fr) | Inhibiteurs raf et leurs utilisations | |
WO2007150015A3 (fr) | Procédé de traitement |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06774658 Country of ref document: EP Kind code of ref document: A2 |